AMLN Amylin Pharmaceuticals, Inc. (MM)

Amylin Pharmaceuticals Announces Public Offering of Common Stock SAN DIEGO, Jan. 21 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (NASDAQ:AMLN) today announced a public offering of 8.0 million shares of common stock at a price of $22.00 per share. The underwriters have a 30-day option to purchase up to 1.2 million additional shares of common stock from the company to cover over-allotments. Morgan Stanley & Co. Incorporated is acting as the sole book running and joint lead manager for the offering. Goldman, Sachs & Co. is acting as joint lead manager of the offering. Co-managers for the offering are Banc of America Securities LLC, J.P. Morgan Securities Inc., and Wachovia Capital Markets, LLC. This announcement is neither an offer to sell nor a solicitation of an offer to buy, nor shall there be any sale of, these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state. A registration statement relating to these securities has been filed with and has been declared effective by the Securities and Exchange Commission. The common stock is being offered in connection with the distribution by the issuer and represents a new financing. Amylin Pharmaceuticals is committed to improving the lives of people with diabetes and other metabolic diseases through the discovery, development and commercialization of innovative, cost-effective medicines. Copies of the final prospectus supplement may be obtained from the Prospectus Departments of Morgan Stanley & Co. Incorporated (1585 Broadway, New York, New York 10036, phone 212-761-6775, fax 212-761-0211), Goldman, Sachs & Co. (Attn: Prospectus Department, 85 Broad Street, New York, New York 10004, phone 212-902-1171, fax 212-902-9316), Banc of America Securities LLC (9 West 57th Street, New York, NY 10019, phone 888-583-8900), J.P. Morgan Securities Inc. (1 Chase Manhattan Plaza, Floor 5B, New York, New York 10081, phone 212-552-5164) and Wachovia Capital Markets, LLC (7 St. Paul Street, Baltimore, Maryland 21202, phone 443-263-6400, fax 443-263-6894). DATASOURCE: Amylin Pharmaceuticals, Inc. CONTACT: Mark G. Foletta, Vice President, Finance and Chief Financial Officer of Amylin Pharmaceuticals, Inc., +1-858-552-2200 Web site: http://www.amylin.com/

Copyright